NCT00529152View on ClinicalTrials.gov

Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Iron Overload
Interventions
DRUG

Deferiprone

Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.

Trial Locations (4)

10010

Cipto Mangunkusumo National Hospital, Jakarta

50603

University of Malaya Medical Center, Kuala Lumpur

Unknown

Abo El Reish Hospital, Cairo University, Cairo

Children Hospital, Ain Shams University, Cairo

Sponsors

Lead Sponsor

ApoPharma
All Listed Sponsors
lead

ApoPharma

INDUSTRY

NCT00529152 - Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients | Biotech Hunter | Biotech Hunter